How I treat with maintenance therapy after allogeneic HCT

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Disease relapse is a primary cause of failure in allogeneic hematopoietic cell transplantation (allo-HCT).
• Maintenance therapy post-allo-HCT is a developing strategy to mitigate relapse and improve long-term patient survival.
• Recent years have seen increased research and clinical application of post-transplant maintenance strategies.

Purpose of the Study:

• To review current data and ongoing studies on maintenance therapy after allo-HCT.
• To address challenges and questions regarding the feasibility and clinical impact of maintenance therapy.
• To present standard practice through common case scenarios of available therapeutic agents.

Main Methods:

• Review of published data and ongoing clinical studies on post-allo-HCT maintenance therapy.
• Discussion of four common case scenarios involving different therapeutic agents.
• Description of current standard practices in the field.

Main Results:

• Maintenance therapy is a critical area of investigation for improving allo-HCT outcomes.
• Several therapeutic agents are available for post-transplant maintenance, but optimal use is still being defined.
• Case scenarios highlight the evolving landscape and practical considerations of maintenance therapy.

Conclusions:

• Maintenance therapy after allo-HCT is crucial for reducing disease relapse.
• Further research and clinical trials are needed to optimize the use of available agents and address remaining challenges.
• Standardizing practice through case-based reviews aids in navigating this rapidly evolving field.